Search Results - "Freeman, Gordon J."

Combination cancer immunotherapy and new immunomodulatory targets by Mahoney, Kathleen M., Rennert, Paul D., Freeman, Gordon J.

“…Key Points Tumours actively inhibit the antitumour immune response. The programmed cell death protein 1–programmed cell death 1 ligand 1 (PD1–PDL1) pathway has…”
Get full text

The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy by Xiao, Yanping, Freeman, Gordon J

“…The microsatellite instable (MSI) subset of colorectal cancer exhibits an active Th1/CTL immune microenvironment, probably due to recognition of a high number…”
Get more information

ICOS:ICOS-Ligand Interaction Is Required for Type 2 Innate Lymphoid Cell Function, Homeostasis, and Induction of Airway Hyperreactivity by Maazi, Hadi, Patel, Nisheel, Sankaranarayanan, Ishwarya, Suzuki, Yuzo, Rigas, Diamanda, Soroosh, Pejman, Freeman, Gordon J., Sharpe, Arlene H., Akbari, Omid

“…Allergic asthma is caused by Th2-cell-type cytokines in response to allergen exposure. Type 2 innate lymphoid cells (ILC2s) are a newly identified subset of…”
Get full text

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family by Schildberg, Frank A., Klein, Sarah R., Freeman, Gordon J., Sharpe, Arlene H.

“…Immune responses need to be controlled for optimal protective immunity and tolerance. Coinhibitory pathways in the B7-CD28 family provide critical inhibitory…”
Get full text

Coinhibitory Pathways in Immunotherapy for Cancer by Baumeister, Susanne H, Freeman, Gordon J, Dranoff, Glenn, Sharpe, Arlene H

“…The immune system is capable of recognizing tumors and eliminates many early malignant cells. However, tumors evolve to evade immune attack, and the tumor…”
Get full text

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance by Zhang, Jinfang, Bu, Xia, Wang, Haizhen, Zhu, Yasheng, Geng, Yan, Nihira, Naoe Taira, Tan, Yuyong, Ci, Yanpeng, Wu, Fei, Dai, Xiangpeng, Guo, Jianping, Huang, Yu-Han, Fan, Caoqi, Ren, Shancheng, Sun, Yinghao, Freeman, Gordon J., Sicinski, Piotr, Wei, Wenyi

“…Abundance of PD-L1, the ligand of the anti-cancer immunotherapy target PD-1, is negatively regulated by poly-ubiquitination via the cyclin D–CDK4/cullin 3–SPOP…”
Get full text

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma by Mahoney, Kathleen M., MD, PhD, Freeman, Gordon J., PhD, McDermott, David F., MD

“…Abstract Purpose Blocking the interaction between the programmed cell death (PD)-1 protein and one of its ligands, PD-L1, has been reported to have impressive…”
Get full text

Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy by Chow, Melvyn T., Ozga, Aleksandra J., Servis, Rachel L., Frederick, Dennie T., Lo, Jennifer A., Fisher, David E., Freeman, Gordon J., Boland, Genevieve M., Luster, Andrew D.

“…Despite compelling rates of durable clinical responses to programmed cell death-1 (PD-1) blockade, advances are needed to extend these benefits to resistant…”
Get full text

Emerging concepts in PD-1 checkpoint biology by Pauken, Kristen E., Torchia, James A., Chaudhri, Apoorvi, Sharpe, Arlene H., Freeman, Gordon J.

“…•The PD-1 pathway plays multifaceted roles in regulating immune responses.•PD-1 can modulate effector and memory T cells, Treg cells, NK cells, and ILCs.•PD-1…”
Get full text

T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity by Schmid, Daniela, Park, Chun Gwon, Hartl, Christina A., Subedi, Nikita, Cartwright, Adam N., Puerto, Regina Bou, Zheng, Yiran, Maiarana, James, Freeman, Gordon J., Wucherpfennig, Kai W., Irvine, Darrell J., Goldberg, Michael S.

“…Targeted delivery of compounds to particular cell subsets can enhance therapeutic index by concentrating their action on the cells of interest. Because…”
Get full text

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy by Pfirschke, Christina, Engblom, Camilla, Rickelt, Steffen, Cortez-Retamozo, Virna, Garris, Christopher, Pucci, Ferdinando, Yamazaki, Takahiro, Poirier-Colame, Vichnou, Newton, Andita, Redouane, Younes, Lin, Yi-Jang, Wojtkiewicz, Gregory, Iwamoto, Yoshiko, Mino-Kenudson, Mari, Huynh, Tiffany G., Hynes, Richard O., Freeman, Gordon J., Kroemer, Guido, Zitvogel, Laurence, Weissleder, Ralph, Pittet, Mikael J.

“…Checkpoint blockade immunotherapies can be extraordinarily effective, but might benefit only the minority of patients whose tumors are pre-infiltrated by…”
Get full text

In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy by Arlauckas, Sean P, Garris, Christopher S, Kohler, Rainer H, Kitaoka, Maya, Cuccarese, Michael F, Yang, Katherine S, Miller, Miles A, Carlson, Jonathan C, Freeman, Gordon J, Anthony, Robert M, Weissleder, Ralph, Pittet, Mikael J

“…Monoclonal antibodies (mAbs) targeting the immune checkpoint anti-programmed cell death protein 1 (aPD-1) have demonstrated impressive benefits for the…”
Get more information

Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy by Gao, Yang, Nihira, Naoe Taira, Bu, Xia, Chu, Chen, Zhang, Jinfang, Kolodziejczyk, Aleksandra, Fan, Yizeng, Chan, Ngai Ting, Ma, Leina, Liu, Jing, Wang, Dong, Dai, Xiaoming, Liu, Huadong, Ono, Masaya, Nakanishi, Akira, Inuzuka, Hiroyuki, North, Brian J., Huang, Yu-Han, Sharma, Samanta, Geng, Yan, Xu, Wei, Liu, X. Shirley, Li, Lei, Miki, Yoshio, Sicinski, Piotr, Freeman, Gordon J., Wei, Wenyi

“…Immunotherapies that target programmed cell death protein 1 (PD-1) and its ligand PD-L1 as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA4) have…”
Get full text

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome by Roemer, Margaretha G M, Advani, Ranjana H, Ligon, Azra H, Natkunam, Yasodha, Redd, Robert A, Homer, Heather, Connelly, Courtney F, Sun, Heather H, Daadi, Sarah E, Freeman, Gordon J, Armand, Philippe, Chapuy, Bjoern, de Jong, Daphne, Hoppe, Richard T, Neuberg, Donna S, Rodig, Scott J, Shipp, Margaret A

“…Classical Hodgkin lymphomas (cHLs) include small numbers of malignant Reed-Sternberg cells within an extensive but ineffective inflammatory/immune cell…”
Get full text

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma by Carey, Christopher D., Gusenleitner, Daniel, Lipschitz, Mikel, Roemer, Margaretha G.M., Stack, Edward C., Gjini, Evisa, Hu, Xihao, Redd, Robert, Freeman, Gordon J., Neuberg, Donna, Hodi, F. Stephen, Liu, Xiaole Shirley, Shipp, Margaret A., Rodig, Scott J.

“…Signaling between programmed cell death protein 1 (PD-1) and the PD-1 ligands (PD-L1, PD-L2) is essential for malignant Hodgkin Reed-Sternberg (HRS) cells to…”
Get full text

TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response by Zeng, Zexian, Wong, Cheryl J, Yang, Lin, Ouardaoui, Nofal, Li, Dian, Zhang, Wubing, Gu, Shengqing, Zhang, Yi, Liu, Yang, Wang, Xiaoqing, Fu, Jingxin, Zhou, Liye, Zhang, Boning, Kim, Sarah, Yates, Kathleen B, Brown, Myles, Freeman, Gordon J, Uppaluri, Ravindra, Manguso, Robert, Liu, X Shirley

“…Abstract Syngeneic mouse models are tumors derived from murine cancer cells engrafted on genetically identical mouse strains. They are widely used tools for…”
Get full text

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer by Ding, Liya, Kim, Hye-Jung, Wang, Qiwei, Kearns, Michael, Jiang, Tao, Ohlson, Carolynn E., Li, Ben B., Xie, Shaozhen, Liu, Joyce F., Stover, Elizabeth H., Howitt, Brooke E., Bronson, Roderick T., Lazo, Suzan, Roberts, Thomas M., Freeman, Gordon J., Konstantinopoulos, Panagiotis A., Matulonis, Ursula A., Zhao, Jean J.

“…PARP inhibitors have shown promising clinical activities for patients with BRCA mutations and are changing the landscape of ovarian cancer treatment. However,…”
Get full text

Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer by Giraldo, Nicolas A, Becht, Etienne, Pagès, Franck, Skliris, Georgios, Verkarre, Virginie, Vano, Yann, Mejean, Arnaud, Saint-Aubert, Nicolas, Lacroix, Laetitia, Natario, Ivo, Lupo, Audrey, Alifano, Marco, Damotte, Diane, Cazes, Aurelie, Triebel, Frederic, Freeman, Gordon J, Dieu-Nosjean, Marie-Caroline, Oudard, Stephane, Fridman, Wolf H, Sautès-Fridman, Catherine

“…Clear cell renal cell carcinoma (ccRCC) has shown durable responses to checkpoint blockade therapies. However, important gaps persist in the understanding of…”
Get full text

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies by CHEN, Benjamin J, CHAPUY, Bjoern, RODIG, Scott J, OUYANG, Jing, SUN, Heather H, ROEMER, Margaretha G. M, XU, Mina L, HONGBO YU, FLETCHER, Christopher D. M, FREEMAN, Gordon J, SHIPP, Margaret A

“…Programmed cell death ligand 1 (PD-L1) is an immunomodulatory molecule expressed by antigen-presenting cells and select tumors that engages receptors on T…”
Get full text

TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine by Jemielity, Stephanie, Wang, Jinyize J, Chan, Ying Kai, Ahmed, Asim A, Li, Wenhui, Monahan, Sheena, Bu, Xia, Farzan, Michael, Freeman, Gordon J, Umetsu, Dale T, Dekruyff, Rosemarie H, Choe, Hyeryun

“…Human T-cell Immunoglobulin and Mucin-domain containing proteins (TIM1, 3, and 4) specifically bind phosphatidylserine (PS). TIM1 has been proposed to serve as…”
Get full text